Short-term and low-dose liraglutide plus metformin decreased body mass index and insulin resistance more than metformin alone in obese women with polycystic ovary syndrome: An open-label randomized controlled study

Background and objectives: Reduction of weight improves different manifestations polycystic ovary syndrome (PCOS). This study compared the effects liraglutide plus metformin versus alone on loss metabolic profiles in obese women with PCOS. Methods: open-label randomized controlled clinical trial consecutively recruited newly-diagnosed PCOS patients reproductive age obesity (body mass index ≥ 27.5 kg/m2). Following randomization into two equal groups, Group-1 received treatment 1000 mg daily while Group-2 was given subcutaneous (SC) 1.2 for 12 weeks. Anthropometric, biochemical hormonal data ovarian morphology were assessed at baseline after Clinical information side recorded every four weeks initiation treatment. Glucose, lipids, all hormones analyzed by glucose oxidase, precipitation method, chemiluminescent microparticle immunoassay respectively. Insulin resistance measured homeostatic model assessment (HOMA-IR). Results: Study included 30 participants comprising 15 each group. Among participants, 5 dropped out from 1 Group-2. The final analysis done among 24 (Gr-1: 10 Gr-2: 14). Waist hip circumference (WC, HC) significantly (p <0.05) decreased treated only metformin. Menstrual irregularity, BMI index), HC, systolic blood pressure (BP), 2h-OGTT glucose, fasting insulin, HOMA-IR < 0.05) to status. Percentage changes weight, improved cases than those Group-1. Side though numerically higher patients, but reduced time. Conclusions: Addition superior lowering insulin acceptable effects. IMC J Med Sci. 2024; 18(1):002. DOI: https://doi.org/10.55010/imcjms.18.002 *Correspondence: Muhammad Abul Hasanat, Room# 1524, Level-15, Block-D, Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbag, Dhaka-1000, Bangladesh. ORCID iD: orcid.org/0000-0001-8151-9792; Email: [email protected]